Callitas Health Enters into Exclusive Development and Intellectual Property Agreement for CannaMint Strips and Files Additional Trademarks for CannaStrips and CanRelief
May 24, 2018 08:30 ET
|
Callitas Health Inc.
CINCINNATI, OH, May 24, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development and...
Callitas Health Signs Dr. Gregory Smith MD, MPH, as the Company's Chief Medical Cannabis Advisor
May 21, 2018 10:55 ET
|
Callitas Health Inc.
CINCINNATI, OH, May 21, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE:LILY) (OTCQB:MPHMF) (FWB:T3F2), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development and...
Callitas Health Interim President & CEO Will Present at the 2018 Proactive's CEO Investors Forum
May 09, 2018 08:30 ET
|
Callitas Health Inc.
CINCINNATI, OH & NEW YORK, NY, May 09, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) an integrated clinical-stage...
Callitas Health, Inc. Releases Annual Update Letter to Shareholders
April 19, 2018 09:46 ET
|
Callitas Health Inc.
CINCINNATI, OH, April 19, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCBB: MPHMF, FWB: T3F2) today announced that Interim President and Chief Executive Officer, James Thompson, has...
Callitas Health, Inc. Signs Multiple Letters of Intent for Distribution of CannaMint Strips in California
April 16, 2018 08:00 ET
|
Callitas Health Inc.
CINCINNATI, OH & LOS ANGELES, CA , April 16, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCBB: MPHMF, FWB: T3F2), (the "Company" or “Callitas”) an integrated clinical-stage...
Callitas Health Announces Response from US FDA on Orphan Drug Designation and Rare Pediatric Disease Designation Requests
March 15, 2018 08:30 ET
|
Callitas Health Inc.
CINCINNATI, OH, March 15, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) a clinical-stage company developing innovative...
UPDATE: Callitas Health Announces Selection of TraDigitalIR as Investor and Public Relations Advisor
March 15, 2018 06:00 ET
|
Callitas Health Inc.
CINCINNATI and NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) a clinical-stage company developing innovative...
Callitas Health Announces Selection of TraDigitalIR as Investor and Public Relations Advisor
March 13, 2018 12:10 ET
|
Callitas Health Inc.
CINCINNATI and NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) a clinical-stage company developing innovative...
Callitas Health, Inc Receives Notice of Allowance from USPTO for Patent Application for Treatment for Male Infertility and Sub-Fertility
March 08, 2018 18:17 ET
|
Callitas Health Inc.
CINCINNATI, OH , March 08, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) a clinical-stage company developing innovative...
Callitas Health Inc., Announces New Partnership with NFI Consumer Healthcare's e.p.t. Pregnancy Test Line
March 05, 2018 11:27 ET
|
Callitas Health Inc.
CINCINNATI, OH, March 05, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCBB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) a clinical-stage company developing innovative...